New study aims to find best first immunotherapy for advanced liver cancer
NCT ID NCT07147101
First seen Apr 24, 2026 · Last updated Jun 23, 2026 · Updated 6 times
Summary
This study is observing 150 adults with advanced liver cancer who are starting immunotherapy for the first time. Researchers will track how well different drug combinations shrink tumors and how the immune system changes. The goal is to learn which treatments work best and why, without assigning participants to a specific therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital, Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Immunotherapy drugs (sintilimab, camrelizumab, nivolumab, ipilimumab, bevacizumab biosimilar, rivoceranib)
What this could lead to
If successful, this could help identify which immunotherapy combinations work best for advanced liver cancer, potentially improving treatment choices.
What could go wrong
This is an observational study, not a controlled trial, so results may not prove cause and effect. The sample size is small (150 people), and findings may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.